[Sultopride, treatment of choice for psychomotor agitation in severe encephalopathy. 33 cases in a neuropediatric milieu].
Thirty-three patients showing a definite group of symptoms including chiefly agitation or self-mutilation often dramatic have been treated with sultopride at doses ranging from 7 to 50 mg/kg/day at the Institut Médico-Pédagogique de l'Enfant-Jésus at Ciney. Forty-eight per cent showing this particular symptoms have been cured or greatly improved with sultopride. In 36% the response was incomplete in that it appeared to be identical with sultopride solely or with the previous medications. An opposite result has been noted in 16% only. Side-effects consisted in extra-pyramidal symptoms, drowsiness and digestive disorders. This study leads to the conclusion that sultopride can be considered as the most efficient therapeutical approach to the management of agitation or self-mutilation in severe encephalopathy.
D000293:Adolescent; D000328:Adult; D000077582:Amisulpride; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D011595:Psychomotor Agitation / Q000188:drug therapy*; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012652:Self Mutilation / Q000188:drug therapy; D013469:Sulpiride / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D011619:Psychotropic Drugs; D013469:Sulpiride; D000077582:Amisulpride
Le sultopride, traitement de choix de l'agitation psycho-motrice chez l'encéphalopathe profond. A propos de 33 cas en milieu neuropédiatrique.